KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Profit After Tax (2016 - 2025)

Historic Profit After Tax for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $188.0 million.

  • AbbVie's Profit After Tax fell 8797.95% to $188.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 5330.34%. This contributed to the annual value of $4.3 billion for FY2024, which is 1204.6% down from last year.
  • As of Q3 2025, AbbVie's Profit After Tax stood at $188.0 million, which was down 8797.95% from $941.0 million recorded in Q2 2025.
  • AbbVie's 5-year Profit After Tax high stood at $4.5 billion for Q1 2022, and its period low was -$22.0 million during Q4 2024.
  • For the 5-year period, AbbVie's Profit After Tax averaged around $1.8 billion, with its median value being $1.4 billion (2024).
  • Its Profit After Tax has fluctuated over the past 5 years, first surged by 1113333.33% in 2021, then crashed by 10267.64% in 2024.
  • AbbVie's Profit After Tax (Quarter) stood at $4.0 billion in 2021, then tumbled by 38.85% to $2.5 billion in 2022, then crashed by 66.76% to $822.0 million in 2023, then crashed by 102.68% to -$22.0 million in 2024, then soared by 954.55% to $188.0 million in 2025.
  • Its last three reported values are $188.0 million in Q3 2025, $941.0 million for Q2 2025, and $1.3 billion during Q1 2025.